维普期刊资源整合服务平台（V6.5）

95篇 您的检索式：作者名="Folprecht"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer显示文摘Gastric cancer is the fifth most frequently occurring can-cer worldwide.China has the largest gastric cancer pop-ulation and nearly half of the patients are diagnosed as advanced-stage[1].The prognosis of most patients with advanced gastric cancer(AGC)remains dismal even despite the approval of several novel chemotherapy drugs and targeted therapy agents.Similarly,immune check-point inhibitors(ICIs)such as programmed death-1(PD-1)antibody have shown promising activity in various solid tumors.Two PD-1 antibodies,pembrolizumab[2]and nivolumab[3],were approved for AGC patients who had treatment failure with chemotherapy.However,the overall response rate(ORR)and the survival benefits of pembrolizumab(11.6%;OS 5.6 months)and nivolumab(nivolumab vs placebo ORR 11%vs 0%,P<0.0001;OS 5.3 vs 4.1 months,P<0.0001)were moderate.	Gunnar Folprecht	2019	Cancer Communications2019，39，1：	5
2	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial显示文摘	Gunnar Folprecht Thomas Gruenberger Wolf O Bechstein Hans-Rudolf Raab Florian Lordick J?rg T Hartmann Hauke Lang Andrea Frilling Jan Stoehlmacher Jürgen Weitz Ralf Konopke Christian Stroszczynski Torsten Liersch Detlev Ockert Thomas Herrmann Eray Goekkurt	2010	Lancet Oncology2010，，1：	3
3	Cetuximab plus FOLFIRI:final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome 显示文摘	Van CE Lang I Folprecht G	2010	J Clin Onco12010，28，15：	1
4	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates显示文摘	Folprecht G Grothey A Alberts S	2005	Ann 0ncol2005，16，8：	1
5	Diagnosis of and Therapy for Hepatocellular Carcinoma显示文摘	T. Greten N. Malek S. Schmidt J. Arends P. Bartenstein W. Bechstein T. Bernatik M. Bitzer A. Chavan M. Dollinger D. Domagk O. Drognitz M. Düx S. Farkas G. Folprecht P. Galle M. Gei?ler G. Gerken D. Habermehl T. Helmberger K. Herfarth R. Hoffmann M. Holtma	2013	Z Gastroenterol2013，，11：	1
6	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial 显示文摘	Folprecht G Gruenberger T Bechstein WO	2010	Lancet Oncol2010，11，1：	1
7	Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials 显示文摘	Folprecht G Cunningham D Ross P	2004	Ann Oncol2004，15，9：	1
8	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial显示文摘	Folprecht G Gruenberger T Bechstein WO	2010	Lancet Oncol2010，11，1：	1
9	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates 显示文摘	Folprecht G Grothey A Alberts S	2005	Ann Oncol2005，16，8：	1
10	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial显示文摘	Folprecht G Gruenberger T Bechstein WO	2010	Lancet Oncol2010，11，：	1
11	Accomplishments in 2008 in the management of curable metastatic colorectal cancer显示文摘	Adam R Hoti E Folprecht G	2009	Gas- trointest Canrer Res2009，3，2：	1
12	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma显示文摘	Lutz M P Schoffski P	2006	Ann Oncol2006，17，3：	1
13	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab , the CELIM randomised phase 2 trial 显示文摘	Folprecht G Gruenberger T Bechstein WO	2010	Lancet Onco12010，11，1：	1
14	Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer显示文摘	Folprecht G Kohne CH Lutz MP	2007	Cancer Treat Res2007，134，：	1
15	Cetuximab and irinote-can/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma显示文摘	Folprecht G Lutz MP Sch(o)ffski P	2006	Ann Oncol2006，17，3：	1
16	The role of new agents in the treatment of coloreetal cancer显示文摘	Folprecht G K(o)hne C H	2004	Oncology2004，66，1：	1
17	Introduction: Advances in treatment of metastatic colorectal cancer显示文摘	Folprecht G	2008	Cancer Treat Rev2008，34，12：	1
18	Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study 显示文摘	Schultheis B Folprecht C Kuhlmann J	2013	Ann Oncol2013，24，6：	1
19	Neoadjuvant treatment of unresectable colorectal liver metastases:correlation between tumour response and resection rates显示文摘	Folprecht G Grothey A Alberts S	2005	Ann Oncol2005，16，8：	1
20	Cetuximab and ironotecan /5-fluorouracil/folinic acid is a safe combination for the first(-)line treatment of patients with epidermal growth foctor receptor expressing metastatic colorectal carcinoma显示文摘	Folprecht G Lutz M P Schoffski P	2005	Ann Oncol2005，22，：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示